Contract notice
Section I: Contracting
authority
I.1) Name and addresses
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
4-5 Charnwood Court,, Heol Billingsley, Parc Nantgarw
Cardiff
CF15 7QZ
UK
E-mail: gregg.roberts@wales.nhs.uk
NUTS: UK
Internet address(es)
Main address: http://nwssp.nhs.wales/ourservices/procurement-services/
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://etenderwales.bravosolution.co.uk/web/login.shtml
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://etenderwales.bravosolution.co.uk/web/login.shtml
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
https://etenderwales.bravosolution.co.uk/web/login.shtml
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
BCU-CP-59436 - Detoxification Services
Reference number: BCU-CP-59436
II.1.2) Main CPV code
85312500
II.1.3) Type of contract
Services
II.1.4) Short description
The MHLD Directorate are seeking approval to recommission the inpatient substance misuse detoxification service for North Wales.
The inpatient substance misuse detoxification service is for patients who have physical and/or psychological dependency to one or more substances with physical or psychiatric complications (co-morbidity) if they require a higher level of care than can be provided safely in the community.
North Wales is an outlier in several areas for substance misuse as outlined.
In 2022/2023, 19 of the 22 Local Authority areas in Wales saw a decrease in rates of individuals admitted to hospital with an alcohol-specific condition. The only 3 Local Authority areas that saw an increase were Gwynedd (4 per cent) Anglesey (7 per cent) and Wrexham (10 per cent).
Betsi Cadwaladr University Health Board (BCUHB) area has the highest rate of admissions related to illicit drugs (152.1 per 100,000 population) across Wales.
When looking at deaths from drug misuse for 2020-22 by local authority, Wrexham is in the top 5 local authorities with a population prevalence of 8.6 per 100,000 population compared with the Welsh average being 6.6 per 100,000 of the population.
The number of patients referred for inpatient substance misuse detoxification service has steadily increased over the last three years. This is from 194 admissions in 2022, 227 admissions in 2023 and 183 in 2024
To ensure that the existing service delivery model is still fit for purpose a full options appraisal process has been undertaken following the Better Business case methodology and explored a range of potential options including BCUHB delivery and external procurement.
II.1.5) Estimated total value
Value excluding VAT:
5 100 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
85312500
II.2.3) Place of performance
NUTS code:
UKL11
UKL12
UKL13
UKL23
II.2.4) Description of the procurement
The MHLD Directorate are seeking approval to recommission the inpatient substance misuse detoxification service for North Wales.
The inpatient substance misuse detoxification service is for patients who have physical and/or psychological dependency to one or more substances with physical or psychiatric complications (co-morbidity) if they require a higher level of care than can be provided safely in the community.
North Wales is an outlier in several areas for substance misuse as outlined.
In 2022/2023, 19 of the 22 Local Authority areas in Wales saw a decrease in rates of individuals admitted to hospital with an alcohol-specific condition. The only 3 Local Authority areas that saw an increase were Gwynedd (4 per cent) Anglesey (7 per cent) and Wrexham (10 per cent).
Betsi Cadwaladr University Health Board (BCUHB) area has the highest rate of admissions related to illicit drugs (152.1 per 100,000 population) across Wales.
When looking at deaths from drug misuse for 2020-22 by local authority, Wrexham is in the top 5 local authorities with a population prevalence of 8.6 per 100,000 population compared with the Welsh average being 6.6 per 100,000 of the population.
The number of patients referred for inpatient substance misuse detoxification service has steadily increased over the last three years. This is from 194 admissions in 2022, 227 admissions in 2023 and 183 in 2024
To ensure that the existing service delivery model is still fit for purpose a full options appraisal process has been undertaken following the Better Business case methodology and explored a range of potential options including BCUHB delivery and external procurement.
Please see Information for Bidders document on the Bravo Solutions portal for further details.
Betsi Cadwaladr University Health Board recognises the importance of the Welsh language to the communities it serves. Consequently, responses to an invitation to quote or tender will be accepted in Welsh as well as English. However, please note that tender responses submitted only in Welsh will be translated by the Trust into English before consideration. Those involved in translating the document will be barred from taking decisions on awarding tenders.
The tender will be awarded based on 30% cost & 70% quality as detailed in the ITT document. Please note that the tender closing date is 07/10/2025 at midday and any late submissions will not be considered.
The etenderwales bravosolution ref:Project: project_59436 and itt_120050
Please direct all queries relating to this tender via the messaging function of the Bravo portal. More details can be found at https://etenderwales.bravosolution.co.uk.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 36
This contract is subject to renewal: Yes
Description of renewals:
an option to extend for two (2) further one (1) year periods, at the discretion of the Health Board and subject to supplier performance.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section III: Legal, economic, financial and technical information
III.1) Conditions for participation
III.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
III.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
III.2) Conditions related to the contract
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
07/10/2025
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
CY
IV.2.7) Conditions for opening of tenders
Date:
07/10/2025
Local time: 12:00
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
Yes
Estimated timing for further notices to be published:
2028
VI.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
VI.3) Additional information
NOTE: The authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at http://www.sell2wales.gov.wales/search/search_switch.aspx?ID=155749
(WA Ref:155749)
The buyer considers that this contract is suitable for consortia.
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.5) Date of dispatch of this notice
16/09/2025